This article was originally published in The Tan Sheet
Ran Gottfried has been appointed to the company's Board of Directors, Perrigo announces Feb. 21. Gottfried is a consultant and director for private and public retailing, distributing, pharmaceutical and telecommunications companies in Israel, the company states. Gottfried also was on the board of the Israeli pharmaceutical company Agis Industries before it was purchased by Perrigo in 2005. He has an "outstanding background in establishing and growing a variety of businesses," Perrigo CEO David Gibbons states...
You may also be interested in...
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.
Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.
Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.